MPI 676

Drug Profile

MPI 676

Alternative Names: MPI-676

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mount Sinai Hospital (Toronto); Wayne State University
  • Developer Meditrina Pharmaceuticals
  • Class Antineoplastics; Nitriles; Small molecules; Triazoles
  • Mechanism of Action Aromatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Endometriosis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Endometriosis in USA (PO)
  • 17 Jul 2008 Preclinical trials in Endometriosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top